

06.03.2023

09:00 - 09:40 **Type: Opening/Closing session** **Amphitheatre Bordeaux**
Title: Welcome to ESMO TAT 2023 and Honorary Award
Moderation: Ruth Plummer, United Kingdom; Lillian Siu, Canada; Anastasios Stathis, Switzerland

09:00 - 09:04 **Welcome to ESMO TAT 2023**
Ruth Plummer¹, Lillian Siu², Anastasios Stathis³, ¹Newcastle University, Newcastle upon Tyne, United Kingdom, ²Princess Margaret Cancer Centre, Toronto, Canada, ³EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland

09:04 - 09:10 **Presentation of 2020-2021-2022 Honorary Awards (Profs. Lillian Siu, Ruth Plummer, Lesley Seymour)**
Anastasios Stathis, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland

09:10 - 09:15 **Introduction to the 2023 Honorary Award keynote lecture**
Ruth Plummer, Newcastle University, Newcastle upon Tyne, United Kingdom

09:15 - 09:40 **Epigenetic therapies: Have they come of age?**
Susan Bates, Columbia University, New York, United States of America

09:45 - 11:15	Type: Educational Title: Pre-clinical models and schedule testing Moderation: Shivaani Kummar, United States of America; Daniel Shao Weng Tan, Singapore	Amphitheatre Bordeaux
09:45 - 10:05	Preclinical modelling to support contemporary drug development <u>Shivaani Kummar</u> , OHSU Knight Cancer Institute - Center for Health and Healing Building 1 - South Waterfront, Portland, United States of America	
10:05 - 10:25	Developing drugs from bench to bedside <u>Sarah Blagden</u> , Churchill Hospital - Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom	
10:25 - 10:45	Development of novel tracers/radiopharmaceuticals in oncology <u>Uwe Haberkorn</u> , NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, Germany	
10:45 - 11:05	Credentialing biomarkers for patient selection <u>Daniel Shao Weng Tan</u> , NCCS - National Cancer Centre Singapore, Singapore, Singapore	
11:05 - 11:15	Q&A	
11:15 - 11:45	Type: Break Title: Coffee break	Hall Bordeaux

11:45 - 12:45	Type: Abstract session Title: Mini Oral session: Optimal tools and methods for developing and implementing precision therapeutics	Amphitheatre Bordeaux
11:45 - 11:50	70MO - Genomic profiling to expand precision cancer medicine in the real world: The ROME trial <u>Andrea Botticelli</u> , Sapienza University of Rome, Rome, Italy	
11:50 - 11:55	28MO - Adapting the Time-to-Event Continual Reassessment Method (TiTE-CRM) to include consolidation immunotherapy in a phase I drug-radiotherapy platform trial <u>Jessica Kendall</u> , University of Leeds - Leeds Institute of Clinical Trials Research (LICTR), Leeds, United Kingdom	
11:55 - 12:00	79MO - Developing international consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: The DEFINE (Dose Finding Extensions) study <u>Olga Solovyeva</u> , The Institute of Cancer Research, Belmont, United Kingdom	
12:00 - 12:05	80MO - Optimising participant flow diagrams for phase I clinical trials <u>Emily Alger</u> , ICR - The Institute of Cancer Research - North Site, Sutton, United Kingdom	
12:05 - 12:15	Invited Discussant <u>Jordi Rodon</u> , The University of Texas M. D. Anderson Cancer Center, Houston, United States of America	
12:15 - 12:25	Oncology phase I trial design and conduct: Time for a change - MDICT Guidelines 2022 <u>Lesley Seymour</u> , Canadian Cancer Trials Group, Kingston, Canada	
12:25 - 12:45	Panel discussion <u>Ruth Plummer</u> ¹ , <u>Jordi Rodon</u> ² , <u>Lesley Seymour</u> ³ , <u>Lillian Siu</u> ⁴ , <u>Anastasios Stathis</u> ⁵ , <u>Christina Yap</u> ⁶ , ¹ Newcastle University, Newcastle upon Tyne, United Kingdom, ² The University of Texas M. D. Anderson Cancer Center, Houston, United States of America, ³ Canadian Cancer Trials Group, Kingston, Canada, ⁴ Princess Margaret Cancer Centre, Toronto, Canada, ⁵ EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland, ⁶ ICR - The Institute of Cancer Research, Sutton, United Kingdom	
12:45 - 13:45	Type: Break Title: Lunch	Hall Bordeaux

12:55 - 13:40	Type: Workshop Title: Workshop in collaboration with ESMO YOC: Selecting patients with molecular imaging for anticancer treatment Moderation: Elene Mariamidze, Georgia; Rille Pihlak, United Kingdom	Room 341
12:55 - 13:05	Selecting patients with molecular imaging for cancer treatment with radiopharmaceutical therapy <u>Ken Herrmann</u> , University Hospital Essen Westdeutsches Tumorzentrum, Essen, Germany	
13:05 - 13:15	Selecting patients with molecular imaging for cancer treatment with medicines <u>Derk Jan De Groot</u> , UMCG - University Medical Center Groningen, Groningen, Netherlands	
13:15 - 13:40	Q&A and discussion	
13:50 - 15:20	Type: Educational Title: Brain penetrance of drugs Moderation: Juanita Lopez, United Kingdom; Jordi Rodon, United States of America	Amphitheatre Bordeaux
13:50 - 14:10	Validating targets and improving brain penetrance of targeted therapies <u>Igor Vivanco</u> , KCL - King's College London, London, United Kingdom	
14:10 - 14:30	Chemical aspects of developing brain penetrant agents <u>Meredith Eno</u> , Blueprint Medicines - Global Headquarters, Cambridge, United States of America	
14:30 - 14:50	Use of targeted USS to disrupt the BBB for drug delivery <u>Jeffrey Weinberg</u> , The University of Texas MD Anderson Cancer Center, Houston, United States of America	
14:50 - 15:10	Immunotherapy for brain cancer: Reimagining the pharmacological audit trail for drug delivery for brain tumours <u>Juanita Lopez</u> , The Royal Marsden Hospital NHS Foundation Trust, Sutton, United Kingdom	
15:10 - 15:20	Q&A	
15:20 - 15:45	Type: Break Title: Coffee break	Hall Bordeaux

15:45 - 17:15	Type: Educational Title: Cell therapy Moderation: Fiona Thistlethwaite, United Kingdom; Elena Garralda Cabanas, Spain	Amphitheatre Bordeaux
15:45 - 16:05	Neoantigen specific TIL for solid tumours <u>Elena Garralda Cabanas</u> , Vall d'Hebron University Hospital, Barcelona, Spain	
16:05 - 16:25	New advances in CRISPR technology for cellular therapy <u>Eliana Ruggiero</u> , IRCCS Ospedale San Raffaele, Milan, Italy	
16:25 - 16:45	Mechanisms of resistance in CAR-T <u>Niels Van De Donk</u> , UMC - University Medical Center Utrecht, Utrecht, Netherlands	
16:45 - 17:05	Biomarkers for toxicities in cell therapy <u>Fiona Thistlethwaite</u> , The Christie NHS Foundation Trust, Manchester, United Kingdom	
17:05 - 17:15	Q&A	

07.03.2023

08:00 - 08:45	Type: Workshop Title: Workshop in collaboration with ESMO YOC: Data integrity and data sharing Moderation: Elene Mariamidze, Georgia; Rille Pihlak, United Kingdom	Room 341
----------------------	--	-----------------

08:00 - 08:10	Artificial Intelligence: How to use technology to obtain the truth <u>Rudolf Fehrmann</u> , UMCG - University Medical Center Groningen, Groningen, Netherlands
08:10 - 08:20	Research Integrity: Does our system of peer-review and academic success contribute to a culture of mis-information? <u>Lee Ellis</u> , University of Texas MD Anderson Cancer Center, Houston, United States of America
08:20 - 08:45	Q&A and discussion

08:50 - 09:20	Type: Keynote lecture Title: Keynote address Moderation: Lillian Siu, Canada	Amphitheatre Bordeaux
----------------------	--	------------------------------

08:50 - 08:55	Introduction to the Keynote lecture <u>Lillian Siu</u> , Princess Margaret Cancer Centre, Toronto, Canada
08:55 - 09:20	Novel insights in mutational signatures uncovered through whole genome sequencing of cancer and experimental models <u>Serena Nik-Zainal</u> , University of Cambridge-Wellcome Trust Centre for Stem Cell Research, Cambridge, United Kingdom

09:30 - 11:00	Type: Educational Title: Novel kinase inhibitors Moderation: Alison Schram, United States of America; Stefan Symeonides, United Kingdom	Amphitheatre Bordeaux
09:30 - 09:50	The latest on CDK 4/6 in breast cancer <u>Violeta Serra Elizalde</u> , Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, Spain	
09:50 - 10:10	BRAF inhibitors: Targeting class II/III alterations <u>Alison Schram</u> , MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States of America	
10:10 - 10:30	KRAS inhibitors beyond G12C <u>Fabrice Barlesi</u> , Gustave Roussy - Cancer Campus, Villejuif, France	
10:30 - 10:50	EGFR and/or HER20 exon 20 inhibitors <u>Matthew Krebs</u> , The Christie NHS Foundation Trust, Manchester, United Kingdom	
10:50 - 11:00	Q&A	
11:00 - 11:30	Type: Break Title: Coffee break	Hall Bordeaux

11:30 - 13:00	Type: Educational Title: Oral immunotherapy Moderation: Eric Van Cutsem, Belgium; Shivaani Kummar, United States of America	Amphitheatre Bordeaux
11:30 - 11:50	Small molecules to modulate TCR signalling <u>Deanna Mele</u> , AstraZeneca, Boston, United States of America	
11:50 - 12:10	Oral PDL1 targeting <u>Eric Van Cutsem</u> , UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium	
12:10 - 12:30	JAK inhibitors as IO therapy <u>Corey J. Langer</u> , Hospital of the University of Pennsylvania, Philadelphia, United States of America	
12:30 - 12:50	Targeting pro-tumorigenic inflammation with oral immunotherapy <u>Santiago Zelenay</u> , Cancer Research UK Manchester Institute, Manchester, United Kingdom	
12:50 - 13:00	Q&A	
13:00 - 14:00	Type: Break Title: Lunch	Hall Bordeaux
13:10 - 13:55	Type: Workshop Title: Workshop in collaboration with ESMO YOC: Drug repurposing trials Moderation: Elene Mariamidze, Georgia; Rille Pihlak, United Kingdom	Room 341
13:10 - 13:20	Why is this important? Trials versus off-label use <u>Kjetil Tasken</u> , Oslo University Hospital - The Norwegian Radium Hospital, Oslo, Norway	
13:20 - 13:30	International collaboration and data-sharing for rare targets <u>Hans Gelderblom</u> , LUMC - Leids Universitair Medisch Centrum, Leiden, Netherlands	
13:30 - 13:55	Q&A and discussion	

14:00 - 15:00	Type: Industry Satellite Symposium Title: Seagen - ADCs' journey into clinical use - Key considerations for improved outcomes Moderation: Solange Peters, Switzerland	Amphitheatre Bordeaux
14:00 - 14:05	Introduction <u>Solange Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland	
14:05 - 14:20	An overview of current approaches utilizing ADCs <u>Solange Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland	
14:20 - 14:35	New ADC targets on the horizon <u>Antoine Hollebecque</u> , Institut Gustave Roussy, Villejuif, Cedex, France	
14:35 - 14:50	Leveraging immune stimulatory ADCs to target immune checkpoints <u>Elena Garralda Cabanas</u> , Vall d'Hebron University Hospital, Barcelona, Spain	
14:50 - 15:00	Q&A and discussion	
15:15 - 16:45	Type: Educational Title: Phase I trial methodology Moderation: Christina Yap, United Kingdom; Toshio Shimizu, Japan	Amphitheatre Bordeaux
15:15 - 15:35	Novel trial designs (including randomised phase I trials) <u>Martijn Lolkema</u> , Amgen Europe B.V., Breda, Netherlands	
15:35 - 15:55	Advancement of statistical methodology and their practical implementation over the decade for phase I trials <u>Christina Yap</u> , ICR - The Institute of Cancer Research, Sutton, United Kingdom	
15:55 - 16:15	Incorporating PK in dose-finding trials <u>Sarah Zohar</u> , Institut national de la santé et de la recherche médicale, Paris, France	
16:15 - 16:35	Pharmacodynamic endpoints in FIH trials <u>Udai Banerji</u> , The Institute of Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom	
16:35 - 16:45	Q&A	
16:45 - 17:05	Type: Break Title: Coffee break	Hall Bordeaux

17:05 - 18:20	Type: Abstract session Title: Proffered Paper session Moderation: Lillian Siu, Canada; Anastasios Stathis, Switzerland	Amphitheatre Bordeaux
17:05 - 17:15	270 - First-in-class first-in-human phase I trial of RBN-2397 in patients with advanced solid tumors validates PARP7 as a novel anticancer therapeutic target <u>Timothy Yap</u> , The University of Texas M. D. Anderson Cancer Center, Houston, United States of America	
17:15 - 17:25	460 - Preliminary results from a phase IA trial of selective FGFR1-3 inhibitor CPL304110 in patients with FGFR-deregulated advanced solid malignancies <u>Iwona Lugowska</u> , Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland	
17:25 - 17:35	Invited Discussant <u>Stefan Symeonides</u> , Edinburgh Cancer Centre Western General Hospital, Edinburgh, United Kingdom	
17:35 - 17:45	1090 - Phase I study of MEDI9253, a recombinant Newcastle Disease Virus encoding interleukin-12, in combination with durvalumab in participants with select advanced/metastatic solid tumors <u>Sophie Postel-Vinay</u> , Institut Gustave Roussy, Villejuif, France	
17:45 - 17:55	10 - Safety, pharmacokinetics, efficacy, and biomarker results of SRK-181 (a latent TGFβ1 inhibitor) from a phase I trial (DRAGON trial) <u>Timothy Yap</u> , MD Anderson Cancer Center, Houston, United States of America	
17:55 - 18:05	Invited Discussant <u>Irene Braña</u> , Vall d'Hebron University Hospital, Barcelona, Spain	
18:05 - 18:20	Q&A	

08.03.2023

08:00 - 08:45 **Type: Workshop** **Room 341**
Title: Workshop in collaboration with ESMO YOC: Phase I design in the era of Project Optimus
Moderation: Elene Mariamidze, Georgia; Rille Pihlak, United Kingdom

08:00 - 08:10 **Importance, background**
Alastair Greystoke, The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, United Kingdom

08:10 - 08:20 **Practical recommendations**
Lesley Seymour, Canadian Cancer Trials Group, Kingston, Canada

08:20 - 08:45 **Q&A and discussion**

08:50 - 10:20 **Type: Educational** **Amphitheatre Bordeaux**
Title: Next-generation macro-molecules
Moderation: Sophie Postel-Vinay, France; Giuseppe Curigliano, Italy

08:50 - 09:10 **Human costimulatory bispecific antibodies in cancer immunotherapy**
Paul Parren, LUMC-Leiden University Medical Center, Leiden, Netherlands

09:10 - 09:30 **Biomarkers to predict response to ADCs**
Giuseppe Curigliano, IEO - Istituto Europeo di Oncologia, Milan, Italy

09:30 - 09:50 **Radioligand therapy across disease: Challenges and opportunities**
Jolanta Kunikowska, University of Warsaw, Warsaw, Poland

09:50 - 10:10 **New pathways to target DNA repair**
Sophie Postel-Vinay, Institut Gustave Roussy, Villejuif, France

10:10 - 10:20 **Q&A**

10:20 - 10:40 **Type: Break** **Hall Bordeaux**
Title: Coffee break

10:40 - 12:10	Type: Educational Title: Predictive and pharmacodynamic biomarkers Moderation: Kurt Schalper, United States of America; Matthew Krebs, United Kingdom	Amphitheatre Bordeaux
10:40 - 11:00	Biomarker role and potential of single-cell and spatially resolved multiparametric analysis <u>Kurt Schalper</u> , Yale School of Medicine - Interventional Radiology Yale Cancer Center, New Haven, United States of America	
11:00 - 11:20	Tumour microenvironment heterogeneity: How to interpret as a biomarker <u>Fernanda Herrera</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland	
11:20 - 11:40	Serum IL-8 as a predictive and pharmacodynamic circulating biomarker in cancer immunotherapy <u>Miguel Fernández De Sanmamed Gutiérrez</u> , Clinica Universidad de Navarra, Pamplona, Spain	
11:40 - 12:00	Use of DNA methylation from liquid biopsy in the biomarker armamentarium <u>Caroline Dive</u> , Cancer Research UK Manchester Institute, Manchester, United Kingdom	
12:00 - 12:10	Q&A	
12:15 - 13:15	Type: Break Title: Lunch	Hall Bordeaux
12:20 - 13:05	Type: Workshop Title: Workshop in collaboration with ESMO YOC: How to bring new molecular entities to earlier stages of cancer Moderation: Elene Mariamidze, Georgia; Rille Pihlak, United Kingdom	Room 341
12:20 - 12:30	Mermaid 1 & 2 design <u>Benjamin Besse</u> , Institut Gustave Roussy, Villejuif, France	
12:30 - 12:40	Peri-operative endpoints <u>Patrick Forde</u> , Johns Hopkins University, Baltimore, United States of America	
12:40 - 13:05	Q&A and discussion	

13:15 - 14:45	Type: Educational Title: Prostate cancer Moderation: Christophe Massard, France; Elena Castro Marcos, Spain	Amphitheatre Bordeaux
13:15 - 13:35	How to manage prostate cancer in 2023 <u>Christophe Massard</u> , Gustave Roussy - Cancer Campus, Villejuif, France	
13:35 - 13:55	Update on immune checkpoint inhibitors <u>Pasquale Rescigno</u> , IRCCS - Istituto di Candiolo - FPO, Candiolo, Italy	
13:55 - 14:15	Tumour genomic profiling: What is relevant and how to avoid potential pitfalls <u>Elena Castro Marcos</u> , Hospital Universitario 12 de Octubre, Madrid, Spain	
14:15 - 14:35	Metabolic radiotherapy-lutetium-PSMA therapy <u>Shahneen Sandhu</u> , Peter MacCallum Cancer Centre, Melbourne, Australia	
14:35 - 14:45	Q&A	
14:45 - 15:00	Type: Break Title: Coffee break	Hall Bordeaux

15:00 - 16:30	Type: Educational Title: Viral related malignancies Moderation: Brigette Ma, Hong Kong PRC; Amanda Psyrri, Greece	Amphitheatre Bordeaux
15:00 - 15:20	Cell-based immunotherapeutic approaches against HPV-associated targets (E7) in HPV-associated advanced cancers <u>Scott Norberg</u> , Center for Cancer Research - National Cancer Institute, Bethesda, United States of America	
15:20 - 15:40	EBV-targeting and other immunotherapeutic approaches in the treatment of endemic nasopharyngeal carcinoma <u>Brigette Ma</u> , The Chinese University of Hong Kong, Sha Tin, Hong Kong PRC	
15:40 - 16:00	Immunotherapeutic advances in the treatment of advanced virally associated hepatocellular carcinoma <u>Josep Llovet</u> , IDIBAPS - Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain	
16:00 - 16:20	Therapeutic vaccines and other non-cell based immunotherapeutic advances against HPV16 E7 and E6 in patients with solid cancers <u>Amanda Psyrri</u> , Attikon University Hospital, Haidari, Greece	
16:20 - 16:30	Q&A	
16:30 - 16:35	Type: Opening/Closing session Title: Closing remarks	Amphitheatre Bordeaux